You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

DeepTag-GPRC5D CAR T-cell

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relapse/Refractory Multiple Myeloma Trial in Hangzhou (DeepTag-GPRC5D Targeted CAR T-cells)

Recruiting
  • Relapse/Refractory Multiple Myeloma
  • DeepTag-GPRC5D Targeted CAR T-cells
  • Hangzhou, Zhejiang, China
    The first affiliated hospital of medical college of zhejiang uni
Oct 10, 2023

Relapsed/Refractory Multiple Myeloma, Plasma Cell Leukemia Trial (CAR-T (CAR-GPRC5D))

Not yet recruiting
  • Relapsed/Refractory Multiple Myeloma
  • Plasma Cell Leukemia
  • CAR-T (CAR-GPRC5D)
  • (no location specified)
Feb 26, 2023

Multiple Myeloma Trial in Wuhan (Fludarabine + Cyclophosphamide + BCMA-GPRC5D CAR-T Cells)

Recruiting
  • Multiple Myeloma
  • Fludarabine + Cyclophosphamide + BCMA-GPRC5D CAR-T Cells
  • Wuhan, Hubei, China
    Union Hospital, Tongji Medical College, Huazhong University of S
Aug 11, 2023

Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial (Anti-GPRC5D CAR-T Cells Injection)

Not yet recruiting
  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory
  • Anti-GPRC5D CAR-T Cells Injection
  • (no location specified)
Feb 18, 2023

Multiple Myeloma Trial in Xuzhou (anti-BCMA/GPRC5D CAR-T CELL)

Recruiting
  • Multiple Myeloma
  • anti-BCMA/GPRC5D CAR-T CELL
  • Xuzhou, Jiangsu, China
    Kailin Xu
Aug 19, 2022

Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in Kunming (Anti-GPRC5D CAR-T cells infusion)

Recruiting
  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory
  • Anti-GPRC5D CAR-T cells infusion
  • Kunming, Yunnan, China
  • +1 more
Feb 21, 2023

Relapsed/Refractory Multiple Myeloma, Plasma Cell Leukemia Trial in Wuhan (CAR-T (CAR-GPRC5D))

Recruiting
  • Relapsed/Refractory Multiple Myeloma
  • Plasma Cell Leukemia
  • CAR-T (CAR-GPRC5D)
  • Wuhan, Hu Bei, China
    Tongji Hospital, Tongji Medical College, Huazhong University of
May 17, 2022

Multiple Myeloma Trial in Hangzhou (GPRC5D-CAR-T)

Recruiting
  • Multiple Myeloma
  • Hangzhou, Zhejiang, China
    The first affiliated hospital of medical college of zhejiang uni
Apr 12, 2022

Multiple Myeloma in Relapse Trial in Shenzhen (BCMA/GPRC5D double CAR-T)

Recruiting
  • Multiple Myeloma in Relapse
  • BCMA/GPRC5D double CAR-T
  • Shenzhen, Guangdong, China
    Shenzhen Qianhai Shekou Free Trade Zone Hospital
Sep 28, 2023

Multiple Myeloma Trial (BMCA and GPRC5D dual target CAR-T cells(OriC321))

Not yet recruiting
  • Multiple Myeloma
  • BMCA and GPRC5D dual target CAR-T cells(OriC321)
  • (no location specified)
Apr 5, 2022

Multiple Myeloma Trial in New York (Infusion of MCARH109 T cells)

Active, not recruiting
  • Multiple Myeloma
  • Infusion of MCARH109 T cells
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Jul 5, 2022

Multiple Myeloma, Refractory Multiple Myeloma, Relapse Multiple Myeloma Trial in New York (MCARH125, MCARH109)

Recruiting
  • Multiple Myeloma
  • +2 more
  • MCARH125
  • MCARH109
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Jun 20, 2022

Lymphoma Trial in Seattle (biological, other, procedure)

Not yet recruiting
  • Lymphoma
  • Immune Globulin Infusion (Human), 10% Solution
  • +5 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 21, 2023

Large B-cell Lymphoma, B-cell Lymphoma Trial in Houston (Magrolimab, Rituximab, CAR T leukapheresis)

Not yet recruiting
  • Large B-cell Lymphoma
  • B-cell Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Jun 29, 2023

Advanced Sarcoma Trial (NKG2D-CAR memory T cell)

Not yet recruiting
  • Advanced Sarcoma
  • NKG2D-CAR memory T cell
  • (no location specified)
Oct 17, 2023

T-cell Acute Lymphoblastic Leukemia Trial in Beijing (CD5 CAR-T)

Recruiting
  • T-cell Acute Lymphoblastic Leukemia
  • CD5 CAR-T
  • Beijing, Beijing, China
    Xuanwu Hospital Capital Medical University
Oct 23, 2022

Lymphoma, B-Cell, Relapsed Cancer, Refractory Lymphoma Trial in Boston (Adaptive Bridging Radiation Therapy (ABRT))

Not yet recruiting
  • Lymphoma, B-Cell
  • +7 more
  • Adaptive Bridging Radiation Therapy (ABRT)
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
Aug 16, 2023

Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission, Acute Lymphoblastic Leukemia

Recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • +5 more
  • CAR-20/19-T cells (1 x 10^5 CAR-20/19-T cells/kg)
  • +4 more
  • Milwaukee, Wisconsin
    Medical College of Wisconsin
Sep 22, 2022

Multiple Myeloma Trial (BCMA-TGFß CAR-T cells (0.75 x10^6 cells/kg), BCMA-TGFß CAR-T cells (1 x 10^6 cells/kg), BCMA-TGFß CAR-T

Not yet recruiting
  • Multiple Myeloma
  • BCMA-TGFβ CAR-T cells (0.75 x10^6 cells/kg)
  • +3 more
  • (no location specified)
Jul 28, 2023

T-Cell Acute Lymphoblastic Leukemia/Lymphoma Trial in Beijing (CD5 CAR T (CT125B))

Recruiting
  • T-Cell Acute Lymphoblastic Leukemia/Lymphoma
  • CD5 CAR T (CT125B)
  • Beijing, Beijing, China
    Beijing Gaobo Boren Hospital
Aug 3, 2022

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Chronic Lymphocytic Leukemia Trial in Milwaukee (CAR-20/19-T cells (1.0 x10^5

Completed
Has Results
  • Lymphoma, Non-Hodgkin
  • +3 more
  • CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg)
  • +3 more
  • Milwaukee, Wisconsin
    Froedtert Hospital & Medical College of Wisconsin
Jun 26, 2022

Lymphoma Patients Undergoing CAR-T Cell Therapy: FIL_SAR-CAR

Not yet recruiting
  • Non-hodgkin Lymphoma,B Cell
  • Chimeric Antigen Receptor T-cells (CAR-T) therapy
  • Alessandria, Italy
  • +20 more
Nov 27, 2023

Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Prolymphocytic Leukemia Trial

Recruiting
  • Recurrent Acute Lymphoblastic Leukemia
  • +15 more
  • Anti-CD19/CD20/CD22 CAR T-Cells
  • +2 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Nov 4, 2022

Locally Advanced or Metastatic Solid Tumors Trial in Shanghai (Anti-5T4 CAR-raNK Cells)

Recruiting
  • Locally Advanced or Metastatic Solid Tumors
  • Anti-5T4 CAR-raNK Cells
  • Shanghai, Shanghai, China
    Shanghai East Hospital
Oct 25, 2022

Recurrent Neuroblastoma, Recurrent Osteosarcoma, Refractory Neuroblastoma Trial in Bethesda, Seattle, Madison (Cyclophosphamide,

Recruiting
  • Recurrent Neuroblastoma
  • +3 more
  • Palo Alto, California
  • +3 more
Jan 25, 2023